Regulatory/Legislative News

The FDA has approved Alcon’s AcrySof IQ ReSTOR +3.0 D multifocal toric IOL, according to a company press release.

From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.

The FDA has granted 510(k) clearance for the SMD-Sr90-DA Radionuclide Brachytherapy Source, according to a press release from Salutaris Medical Devices.

The FDA has designated miltefosine as an orphan drug for the treatment of Acanthamoeba keratitis, according to a press release from Profounda.

A registration application for Oxervate eye drops for the treatment of moderate and severe neurotrophic keratitis in adults has been accepted by the European Medicines Agency, according to a Dompé press release.

Eye care has sure seen a lot of changes in 2016, and a look to the year ahead tells us we will probably see more. Here are three continuing trends that are likely to impact the way most of us practice:

Galderma announced it has received FDA approval of two new Restylane products for the treatment of nasolabial folds in patients over the age of 21.

Many pharmaceutical stock prices dropped today after President-elect Donald Trump announced in an interview with Time magazine that he will attempt to bring down drug prices during his presidential term.

The shift to a Trump administration could mean several health insurance changes and the strengthening of Medicaid.

The FDA has granted 510(k) clearance for the Navilas Laser System 577s, a compact, all-digital system for navigated focal and peripheral laser treatments, making it immediately available in the U.S., according to correspondence from OD-OS, the system’s manufacturer.